Development

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

Articles

Advances in palladium-catalyzed hydrogenation, visible-light photocatalysis, and chemocatalyisis for heterocycles are some recent developments.

Seeking Chemocatalytic and Biocatalytic Solutions

Industry, the public sector, and individuals can play an important role in creating solutions.

Tackling Global Health Concerns

In Part III of a three-part article, the authors examine various degradation routes of APIs, impurities arising from interactions in formulations, metabolite impurities, various analytical methods to measure impuritie, and ways to control impurities.

Evaluating Impurities in Drugs (Part III of III)

With financing constrained, biotechnology firms must find ways to sustain innovation.

A Sustainable Biotech Path

Contract API manufacturers and fine-chemical producers roll out capacity and service expansions.

Inside INFORMEX: Evaluating the Market for Contract API Manufacturing

Excipient manufacturers expand production capacity and partner to broaden their offerings.

Expanding Excipient Portfolios

Regulatory bodies, standard-setting organizations, and industry seek to tackle the problem of counterfeit drugs and securing the flow of pharma ingredients.

Securing the Pharma Supply Chain

The divide between innovation and conflict of interest in medical research is not so clear.

Defining Conflict of Interest

Jim Miller is president of PharmSource Information Services, Inc., and publisher of Bio/Pharmaceutical Outsourcing Report.

The evolving bio/pharmaceutical business model poses risk for CMOs.

CMOs Face a Kodak Moment

The author reviews significant changes to GMP for excipients in the forthcoming American National Standard, including a risk-based approach to excipient manufacture, why new requirements were proposed, and their potential impact to excipient manufacturers.

Ingredients